ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas
Abstract
Aims: Sulfonylureas are categorized according to their binding sites of the ATP-sensitive K+ channel (KATP channel) complex in pancreatic β-cells. The binding sites are classified as A, B and A + B site (both A and B sites), respectively. The Ser1369Ala variant in the sulfonylurea receptor gene ABCC8 which encodes a subunit of the KATP channel complex has been demonstrated to be associated with the hypoglycemic effect of gliclazide, which binds to the A site. However, the hypoglycemic effect of the Ser1369Ala variant on treatment with A + B binding site sulfonylureas, such as glimepiride or glibenclamide, is still uncertain. Materials & methods: In a case–control study, 32 patients with Type 2 diabetes admitted to hospital with severe hypoglycemia and 125 consecutive Type 2 diabetic outpatients without severe hypoglycemia were enrolled. We determined the genotypes of the ABCC8 polymorphism (Ser1369Ala) in the patients with or without severe hypoglycemia. All of the patients were taking glimepiride or glibenclamide. Results: In the patients treated with glimepiride or glibenclamide, we found no significant differences in the distribution of the Ser1369Ala genotype between patients with or without severe hypoglycemia (p = 0.26). Moreover, the Ala1369 minor allele tended to be less frequent in the hypoglycemic group (31 vs 43%; OR: 1.65; 95% CI: 0.92–2.96; p = 0.09). Conclusion: Our findings suggest that the Ser1369Ala variant is not a major predictive factor of severe hypoglycemia due to glimepiride or glibenclamide, both of which bind to the A + B site. It is likely that severe hypoglycemia due to A + B binding site sulfonylureas will be mediated by other factors, and not the Ala1369 minor allele.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Zammitt NN, Frier BM: Hypoglycemia in Type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care28,2948–2961 (2005).
- 2 Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV: Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA301,1565–1572 (2009).
- 3 Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V: Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care26,1485–1489 (2003).
- 4 Pearson ER, Donnelly LA, Kimber C et al.: Variation in TCF7L2 influences therapeutic response to sulfonylureas – a GoDARTs study. Diabetes56,2178–2182 (2007).
- 5 Becker ML, Visser, LE, Trienekens, PH, Hofman, A, van Schaik R, Stricker B: Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther.83,288–292 (2008).
- 6 Sattiraju S, Reyes S, Kane GC, Terzic A: K-ATP channel pharmacogenomics: from bench to bedside. Clin. Pharmacol. Ther.83,354–357 (2008).
- 7 Aittoniemi J, Fotinou C, Craig TJ, de Wet H, Proks P, Ashcroft FM: SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. Lond. B. Biol. Sci.364,257–267 (2009).
- 8 Vila-Carriles WH, Zhao GL, Bryan J: Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J.21,18–25 (2007).
- 9 Winkler M, Stephan D, Bieger S, Kuhner P, Wolff F, Quast U: Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A+B-site ligands. J. Pharmacol. Exp. Ther.322,701–708 (2007).
- 10 Hamming KS, Soliman D, Matemisz LC et al.: Coexpression of the Type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel. Diabetes58,2419–2424 (2009).▪▪ First in vitro study demonstrating that the Ala1369 variant does not significantly alter the KATP channel sensitivity to insulin secretagogue, which bind to B or A + B sites, in contrast to A site binding sulfonylureas.
- 11 Feng Y, Mao G, Ren X et al.: Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care31,1939–1944 (2008).▪▪ Large-scale prospective cohort study testing the association between the Ser1369Ala variant in the ABCC8 gene and clinical efficacy of gliclazide.
- 12 Hansen T, Echwald SM, Hansen L et al.: Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes47,598–605 (1998).
- 13 Ohta Y, Tanizawa Y, Inoue H et al.: Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes47,476–481 (1998).
- 14 Babenko AP, Polak M, Cave H et al.: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med.355,456–466 (2006).
- 15 Rafiq M, Flanagan SE, Patch AM et al.: Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care31,204–209 (2008).
- 16 Thomas PM, Cote GJ, Wohllk N et al.: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science268,426–429 (1995)
- 17 Laukkanen O, Pihlajamaki J, Lindstrom J et al.: Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish diabetes Prevention Study. J Clin Endocrinol Metab89,6286–6290 (2004).
- 18 Yokoi N, Kanamori M, Horikawa Y et al.: Association studies of variants in the genes involved in pancreatic β-cell function in Type 2 diabetes in Japanese subjects. Diabetes55,2379–2386 (2006).
- 19 Florez JC, Jablonski KA, Kahn SE et al.: Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the diabetes prevention program. Diabetes56,531–536 (2007).
- 20 Xu HM, Murray M, McLachlan AJ: Influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs. Curr. Drug Metab.10,643–658 (2009).▪ Comprehensive review article regarding the pharmacogenomics of sulfonylureas.
- 21 Rissanen J, Markkanen A, Karkkainen P et al.: Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and Type 2 diabetes but not with altered secretion of insulin. Diabetes Care23,70–73 (2000).
- 22 Gloyn AL, Pearson ER, Antcliff JF et al.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med.350,1838–1849 (2004).
- 23 Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet.5,1809–1812 (1996).
- 24 Holstein A, Hahn M, Stumvoll M, Kovacs P: The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with Type 2 diabetes. Horm. Metab. Res.41,387–390 (2009).
- 25 Holstein A, Plaschke A, Ptak M et al.: Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol.60,103–106 (2005).
- 26 Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG: Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics10,1781–1787 (2009).
- 27 Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics7,405–409 (1997).
